Logo image of AVIR

ATEA PHARMACEUTICALS INC (AVIR) Stock Fundamental Analysis

NASDAQ:AVIR - Nasdaq - US04683R1068 - Common Stock - Currency: USD

3.16  -0.05 (-1.56%)

After market: 3.16 0 (0%)

Fundamental Rating

3

Taking everything into account, AVIR scores 3 out of 10 in our fundamental rating. AVIR was compared to 195 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for AVIR as it has an excellent financial health rating, but there are worries on the profitability. AVIR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AVIR has reported negative net income.
In the past year AVIR has reported a negative cash flow from operations.
AVIR had negative earnings in 4 of the past 5 years.
In the past 5 years AVIR reported 4 times negative operating cash flow.
AVIR Yearly Net Income VS EBIT VS OCF VS FCFAVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

The Return On Assets of AVIR (-31.81%) is comparable to the rest of the industry.
With a decent Return On Equity value of -34.05%, AVIR is doing good in the industry, outperforming 61.03% of the companies in the same industry.
Industry RankSector Rank
ROA -31.81%
ROE -34.05%
ROIC N/A
ROA(3y)-25.47%
ROA(5y)-12.4%
ROE(3y)-26.96%
ROE(5y)-13.16%
ROIC(3y)N/A
ROIC(5y)N/A
AVIR Yearly ROA, ROE, ROICAVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AVIR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVIR Yearly Profit, Operating, Gross MarginsAVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

AVIR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AVIR has more shares outstanding
There is no outstanding debt for AVIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVIR Yearly Shares OutstandingAVIR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AVIR Yearly Total Debt VS Total AssetsAVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

AVIR has an Altman-Z score of 4.42. This indicates that AVIR is financially healthy and has little risk of bankruptcy at the moment.
AVIR has a better Altman-Z score (4.42) than 80.51% of its industry peers.
There is no outstanding debt for AVIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.42
ROIC/WACCN/A
WACCN/A
AVIR Yearly LT Debt VS Equity VS FCFAVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

AVIR has a Current Ratio of 19.94. This indicates that AVIR is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 19.94, AVIR belongs to the best of the industry, outperforming 89.23% of the companies in the same industry.
A Quick Ratio of 19.94 indicates that AVIR has no problem at all paying its short term obligations.
The Quick ratio of AVIR (19.94) is better than 89.23% of its industry peers.
Industry RankSector Rank
Current Ratio 19.94
Quick Ratio 19.94
AVIR Yearly Current Assets VS Current LiabilitesAVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

AVIR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.82%, which is quite good.
EPS 1Y (TTM)15.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AVIR will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.60% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-16.54%
EPS Next 2Y3.53%
EPS Next 3Y8.6%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVIR Yearly Revenue VS EstimatesAVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2026 2027 100M 200M 300M
AVIR Yearly EPS VS EstimatesAVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVIR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVIR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVIR Price Earnings VS Forward Price EarningsAVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVIR Per share dataAVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.53%
EPS Next 3Y8.6%

More info and screens

0

5. Dividend

5.1 Amount

AVIR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATEA PHARMACEUTICALS INC

NASDAQ:AVIR (6/13/2025, 8:00:01 PM)

After market: 3.16 0 (0%)

3.16

-0.05 (-1.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners64.53%
Inst Owner Change-5.39%
Ins Owners4.73%
Ins Owner Change11.23%
Market Cap270.43M
Analysts50
Price Target6.12 (93.67%)
Short Float %4.29%
Short Ratio7.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.82%
Min EPS beat(2)-5.99%
Max EPS beat(2)4.35%
EPS beat(4)3
Avg EPS beat(4)15.89%
Min EPS beat(4)-5.99%
Max EPS beat(4)38.49%
EPS beat(8)6
Avg EPS beat(8)12.05%
EPS beat(12)10
Avg EPS beat(12)18.79%
EPS beat(16)13
Avg EPS beat(16)42.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.23%
EPS NQ rev (1m)1.15%
EPS NQ rev (3m)-3.61%
EPS NY rev (1m)0%
EPS NY rev (3m)-49.35%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.66
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)-1.86
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0
BVpS4.8
TBVpS4.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.81%
ROE -34.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.47%
ROA(5y)-12.4%
ROE(3y)-26.96%
ROE(5y)-13.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.94
Quick Ratio 19.94
Altman-Z 4.42
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
EPS Next Y-16.54%
EPS Next 2Y3.53%
EPS Next 3Y8.6%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.56%
EBIT Next 3Y11.25%
EBIT Next 5YN/A
FCF growth 1Y-34.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.17%
OCF growth 3YN/A
OCF growth 5YN/A